Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Lung Cancer Clinical Trial

Official title:

A Phase Ib, Open-label, Single Center, Non-randomized Study for Safety and Efficacy of TQB2450 Combined With Anlotinib in Patients With Advanced Mutation Positive Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03910270
• Other study ID #: TQB2450-Ib-11
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: April 30, 2019
• Est. completion date: December 31, 2020

Study information

• Verified date: March 2019
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Li Zhang, doctor
• Phone: 020-87343458
• Email: zhangli[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 31, 2020
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Understood and signed an informed consent form.

2. 18 years and older.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life expectancy= 12 weeks.

4. Histologically or cytologically confirmed mutation positive non-small cell lung cancer according to 8th International Association for the Study of Lung Cancer (IASLC) edition.

5. Has measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

6. Adequate organ system function, defined as follows:

1. absolute neutrophil count (ANC) = 1.5×10^9/L, platelets (PLT) = 100×10^9/L, hemoglobin (Hb)= 90g /L;

2. total bilirubin (TBIL) = 1.5×ULN;alanine transaminase (ALT) and aspartate aminotransferase (AST) = 3.0 × ULN (without liver metastasis) or = 5.0 × ULN (with liver metastasis), Creatinine = 1.5 × ULN and creatinine clearance = 50 ml/min;

3. Urine protein < ++,or urine protein = ++ concomitant with content of 24-hour urinary protein <1.0 g;

4. international normalized ratio (INR) = 1.5×ULN, activated partial thromboplastin time (APTT) = 1.5×ULN;

5. left ventricular ejection fraction (LVEF) = 50%;

7. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ; No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.

Exclusion Criteria:

1. Has diagnosed and/or treated additional malignancy within 5 years prior to randomization except of cured in situ carcinoma of the cervix, non-melanoma skin cancer and superficial bladder carcinoma.

2. Has severe hypersensitivity reactions after taking other monoclonal antibodies.

3. Has hypersensitivity reactions after taking anlotinib.

4. Has prior therapy with anlotinib, anti-programmed cell death (PD)-1, anti-PD-L1 or other immunotherapy against PD-1/PD-L1.

5. Has any active autoimmune disease or history of autoimmune disease, such as autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis, asthma patients who need bronchiectasis for medical intervention; Subjects with the vitiligo without systemic treatment, psoriasis, alopecia, well-controlled type I diabetes mellitus, hypothyroidism stable on hormone replacement will not be excluded from this study.

6. Has multiple factors affecting oral medication, such as inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.

7. Has clinical significance of thyroid dysfunctions within 6 months prior to enrollment, and even though medical therapy, thyroid function can not return to normal or no clinical significance.

8. Has central nervous system (CNS) metastases without local therapy of lesion.

9. Radiograph (within 28 days before enrollment) showed that the tumor surrounded important blood vessels, and the investigators determined that entering the study would cause bleeding risk.

10. Hemoptysis (defined as coughing out or spitting out = 1 teaspoon of blood or small blood clots or hemoptysis without sputum) within 28 days before enrollment , not including bloody sputum.

11. Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration.

12. Has any of the following severe acute complications:

1. Unstable angina and/or congestive heart failure or vascular disease requiring hospitalization within 12 months, or other cardiac impairments determined by the investigator, which may affect the evaluation of drug safety; Myocardial infarction or ischemia with ST elevation = 2 mm indicated by electrocardiogram (ECG);

2. Has pulmonary infections and/or acute bacterial or fungal infections requiring intravenous antibiotic therapy;

3. Has clinical jaundice caused by liver dysfunction;

4. Has hypertension and uncontrolled by a single antihypertensive drug treatment, systolic blood pressure = 160 mmHg, diastolic blood pressure = 100 mmHg;

13. Virological test indicates one of the following items before enrollment:

1. HBsAg positive and HBV-DNA = 1 × 10^3 copies/mL;

2. Anti-HCV positive and HCV virus titer detection value exceeds the upper limit of normal value;

3. HIV positive;

14. Has participation in an anti-tumor clinical trial within 28 days prior to the first administration.

15. Has serious affecting safety or treatment compliance concomitant diseases, according to the investigator's judgment.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• TQB2450
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
• Anlotinib
a multi-target receptor tyrosine kinase inhibitor

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR)	Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR)	up to approximately 12 months
Secondary	Progression-free survival (PFS)	PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.	up to approximately 12 months
Secondary	Overall survival (OS)	OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.	up to approximately 15 months
Secondary	Disease control rate(DCR)	Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).	up to approximately 12 months